

Gavi 5.1 (including Pandemic Preparedness & Response)

BOARD MEETING


Aurélia Nguyen

Johannes Ahrendts

7-8 December 2022, Geneva, Switzerland



Recap: Gavi 5.1 journey started in April '22 led by the Board with close PPC involvement



Gavi 5.1 is not a new strategy. A natural evolution of 5.0 serving as bridge to 6.0

Gavi 5.1: proposed targeted updates to Gavi 5.0 'one-pager'

Change vs. Gavi 5.0 'one-pager'

Vision: Leaving no one behind with immunisation

SUSTAINABLE DEVELOPMENT GOALS

Principles: To save lives and protect people's health

Goals: 1 INTRODUCTION OF VACCINES

Objectives: B Support scale up prevention and pandemic response; C Enhance response to relevant stockpiles and strategic allocation of stockpiles

Enablers: • Secure long-term predictable funding for Gavi programmes; • Ensure global political commitment for immunisation, prevention and primary health care; • Use evidence, evaluations and improved data for policies, programmes and accountability; • Leverage the private sector, including through innovative finance mechanisms & partnerships

1 INTRODUCTION AND SCALE UP OF VACCINES

- A** Strengthen countries' **prioritisation of vaccines** appropriate to their context
- B** Support countries to **introduce and scale up coverage of vaccines** for prevention of endemic, epidemic and pandemic diseases
- C** Enhance **outbreak and pandemic response by ensuring equitable access to relevant vaccines through stockpiles through and strategic allocation of stockpiles**

2 STRENGTHEN REGULATORY SERVICES TO INCREASE IMMUNISATION COVERAGE


- A** Help countries **strengthen regulatory services** to regulate **immunised and children** to build health care platforms
- B** Support countries to **strengthen immunisation systems** that are **resilient, well-sustainable, high quality** and meet the needs of the population
- C** Work with countries to **strengthen regulatory services** to build resilient systems, identify and address **barriers** to immunisation

4 ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTS

- A** Ensure sustainable, **healthy markets dynamics with diversified supply** for vaccines and immunisation-related products at affordable prices
- B** Incentivise **innovation** for the development of **suitable vaccines**
- C** Scale up **innovative immunisation-related products**

Building on existing contribution, four areas for targeted expansion of the Alliance's role in PPR

Alliance is significant contributor to PPR



4 priorities areas for expanded role in PPR

- 1 Essential capabilities for next pandemic
- 2 Rapid access to at-risk and contingent funding
- 3 Resilient routine immunisation programmes
- 4 Diversification of regional manufacturing

Covered in separate paper


Now need to build a cohesive Alliance-wide plan to improve critical path capabilities

Financial implications of Gavi 5.1 (1/2)

As per financial forecast v20

Gavi core Forecast (2021-25)


\$ millions, USD




Financial implications of Gavi 5.1 (2/2)

As per financial forecast v20

COVAX AMC Forecast (2020-23)



COVID-19 / PPR Potential Expenditures (2024-25)



Recommendation

The Gavi Alliance Board is requested to:

Approve the updated framework for Gavi 5.1 (updated ‘strategy one-pager’) attached as Annex A to Doc 06.

The Gavi Alliance Board is also requested to **provide guidance** on Gavi’s targeted additional roles in Pandemic Preparedness and Response as outlined in Annex B to Doc 06.

